- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03486613
PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis
Patient-reported Outcome Measures Collected in DANBIO Reported Via a Smartphone App Versus a Touch Screen Solution in an Outpatient Clinic Among Patients With Inflammatory Arthritis: A Randomised Cross-over Agreement Study
Study Overview
Status
Detailed Description
The study is a randomised, within-participants cross-over design trial including 60 patients with rheumatoid arthritis (RA) (20), psoriatic arthritis (PsA) (20) and axial spondyloarthritis (SpA) (20) from the Rheumatology outpatient clinic at Aalborg University Hospital. The participants will be randomised in ratio 1:1 to:
- Group AT (App → Touch) (30 participants) the participant reports data through the DANBIO app on a smartphone first and after a "washout period" of one day via the touch screen solution at the rheumatology outpatient clinic.
- Group TA (Touch → App) (30 participants): the participant reports data through the touch screen solution at the rheumatology outpatient clinic and after a "washout period" of one day via the DANBIO app on a smartphone.
The primary objective is to evaluate whether electronic reporting of PROM through the DANBIO smartphone app is comparable to the traditional touch screen solution in the rheumatology outpatient clinic among patients with inflammatory arthritis in standard clinical care. The primary outcome is HAQ. Secondary outcomes are: VAS pain, VAS fatigue, VAS global Health, BASDAI, BASFI, PASS, Anchoring question, DAS28crp and ASDAS. DAS28crp are estimated using a fixed level for C-reactive protein (CRP) level of 6, swollen joint count of 0.5 and tender joint count of 1. ASDAS are estimated using a fixed level for CRP of 6. These data are based on DANBIO registrations of patients with RA, PsA or SpA from the rheumatology outpatient clinic at Aalborg University Hospital. DAS28crp and ASDAS are estimated from the PROM data to give the clinician an overview of PROM correlating to e.g. remission or high disease activity.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Department of rheumatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A participant will be eligible for study participation if he/she meets the following criteria:
- Diagnosed in DANBIO with RA, PsA or SpA
- Is currently treated and monitored at the rheumatology outpatient clinic at Aalborg University Hospital
- Have previously reported PROM in DANBIO through the touch screen solution at the rheumatology outpatient clinic ≥ 3 times
Exclusion Criteria:
A participant cannot be included in the study if he/she meets any of the following criteria:
- Inability to provide informed consent or unwilling to comply with the study protocol
- Diagnosis of RA, PsA or SpA ≤ 12 months
- Does not have access to a smartphone that can download and run the DANBIO app
- Not able to understand written Danish i.e. cannot understand the Danish version of the PROM questionnaires
- Reduced sight in such degree that the participant cannot read the questionnaire in the smartphone app/on the touch-screen with e.g. glasses
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group AT
PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
|
PROM data is reported through the DANBIO smartphone app
PROM data is reported through the touch screen solution
|
Other: Group TA
PROM registration via the touch screen solution and thereafter the DANBIO App
|
PROM data is reported through the DANBIO smartphone app
PROM data is reported through the touch screen solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Health Assessment Questionnaire (HAQ)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
Assess the patient's physical function
|
day 1 (first data registration) and day 3 (second data registration)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analogue Scale for Pain
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assessment of pain on a scale from 0-100 within the last week.
The left of the scale (0) signifies the absence of pain and the right end (100) maximum pain.
|
day 1 (first data registration) and day 3 (second data registration)
|
Visual Analogue Scale for fatigue
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assessment of fatigue on a scale from 0-100 within the last week.
The left of the scale (0) signifies the absence of fatigue and the right end (100) maximum fatigue.
|
day 1 (first data registration) and day 3 (second data registration)
|
Patient Global Visual Analogue Scale
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's global assessment of disease activity (arthritis severity) on a scale from 0-100 within the last week.
The left of the scale (0) signifies the absence of arthritis activity and the right end (100) maximum arthritis activity.
|
day 1 (first data registration) and day 3 (second data registration)
|
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assessment of essential symptoms in axial arthritis.
The questionnaire consist of six questions regarding essential symptoms in axial arthritis answered on a Visual Analogue Scale from 0-100.
The left of the scale (0) signifies the absence of symptoms and the right end (100) maximum symptoms.
The patient's answer for each individual question are added to a combined score of 0-100, where 0 signifies the absence of symptoms and 100 maximum symptoms.
|
day 1 (first data registration) and day 3 (second data registration)
|
Bath Ankylosing Spondylitis Functional Index (BASFI)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assesment of physical function.
The questionnaire consist of ten questions regarding physical function in axial arthritis answered on a Visual Analogue Scale from 0-100.
The left of the scale (0) signifies the absence of physical limitations and the right end (100) maximum physical limitations.
The patient's answer for each individual question are added to a combined score of 0-100, where 0 signifies the absence physical limitations and 100 maximum physical limitations.
|
day 1 (first data registration) and day 3 (second data registration)
|
Patient Acceptable Symptom State (PASS)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assessment of acceptable symptom state.
Consist of one question answered with "yes" or "no".
The question is: ''Take into account all the ways in which your arthritis has affected you in the past 48 hours.
If you were to remain for the next few months as you are today, would it be acceptable to you?"
|
day 1 (first data registration) and day 3 (second data registration)
|
Anchoring question
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
The patient's assessment of change in arthritis activity since last visit
|
day 1 (first data registration) and day 3 (second data registration)
|
Disease Activity Score 28 joints C-reactive protein (DAS28crp)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
Composite score used as a measurement of disease activity in patients with peripheral arthritis.
The DAS28crp score is based on 28 joint count for tenderness (TJC28) and swelling (SJC28), Patient Global Visual Analogue Scale (GH) and CRP level (CRP).
The DAS28crp equation is: DAS28crp = 0.56square root(TJC28) + 0.28square root(SJC28) + 0.36ln(CRP + 1) + 0.014(GH) + 0.96.
ASDAS = 0.12*Back Pain + 0.06*Morning Stiffness + 0.11*Patient Global + 0.07*Peripheral Pain/Swelling + 0.58*Ln(CRP+1)0.96-9.4
where a score under 2.6 is remission, a score between 2.6-3.1 is low disease activity, a score of 3.2-5.1 is moderate disease activity and a score of 5.1 or higher is high disease activity.
|
day 1 (first data registration) and day 3 (second data registration)
|
Ankylosing Spondylitis Disease Activity Score (ASDAS)
Time Frame: day 1 (first data registration) and day 3 (second data registration)
|
Composite score used as a measurement of disease activity in patients with axial arthritis.
The ASDAS score is based on some of the questions from the BASDAI questionnaire and C-reative protein (CRP).
The ASDAS equation is: ASDAS = 0.12*Back Pain + 0.06*Morning Stiffness + 0.11*Patient Global + 0.07*Peripheral Pain/Swelling + 0.58*Ln(CRP+1).
The scale ranges from 0.6 to infinite where a score under 1.3 is remission, a score between 1.3-2.0 is moderate disease activity, a score of 2.1-3.5 is high disease activity and a score of higher than 3.5 is very high disease activity.
|
day 1 (first data registration) and day 3 (second data registration)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Salome Kristensen, MD, PhD, Department of Rheumatology, Aalborg University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-000367
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on PROM registration via the DANBIO App on a smartphone
-
Salome KristensenCompletedSystemic Lupus ErythematosusDenmark
-
Norwegian University of Science and TechnologyUllevaal University HospitalTerminated
-
University of Santiago de CompostelaMinisterio de Economía y Competitividad, Spain; Ministry of Work and Welfare...Completed
-
Nottingham University Hospitals NHS TrustKing's College Hospital NHS Trust; The Leeds Teaching Hospitals NHS Trust; Manchester... and other collaboratorsRecruitingRespiratory Tract Diseases | Lung Diseases | Cystic Fibrosis | Genetic Disease | Digestive System Disease | Pancreatic DiseaseUnited Kingdom
-
University College, LondonBritish Heart Foundation; Headspace Meditation Limited; Technical University...UnknownWell-being, Work StressUnited Kingdom
-
University of CopenhagenMovesca ApS; Departmen for rehabilitation M3, Hobro HospitalCompletedDigital Clinical Diet Registrations Advantages | Patients in RehabilitationDenmark
-
Hospital Moinhos de VentoNot yet recruiting
-
Maastricht University Medical CenterCompleted
-
Milton S. Hershey Medical CenterPenn State University; Congressionally Directed Medical Research ProgramsRecruiting
-
University of HaifaCompletedExperimental | ControlIsrael